Source:http://linkedlifedata.com/resource/pubmed/id/18360827
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2008-4-16
|
pubmed:abstractText |
Thymomas and thymic carcinomas are peculiar epithelial tumors of the anterior mediastinum. They may show aggressive clinical behavior and are a paradigm for the interaction between the tumor and the immune system. So far, adequate functional studies enabling a better understanding of this malignancy have not been performed, since human thymoma/thymic carcinoma cell lines have not been available. Here, the authors describe the establishment, characterization and functional analyses of epithelial cell lines from a Type B1-thymoma and a poorly differentiated thymic carcinoma. By Fluorescence-activated cell sorting (FACS) analyses, both cell lines were aneuploid. The aneuploid cell fraction of the thymic carcinoma cell line was characterized by a high proliferation index of 55.9%, in contrast to a lower proliferation rate of the aneuploid cell fraction of the thymoma (19.7%). Array-based comparative genomic hybridization (aCGH) and conventional cytogenetic analysis of the thymoma revealed only minor imbalances whereas the thymic carcinoma was characterized by a complex karyotype in the hyperdiploid range that was readily defined with multicolor FISH (mFISH). Application of a selective COX-2 inhibitor reduced cell viability in both cell lines in a dose-dependent manner. In conclusion, these first cell lines of a thymoma and a CD5-positive thymic carcinoma are useful tools for further in vitro studies of cellular, molecular and genetic aspects of the disease and for functional tests to evaluate new therapeutic targets.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1097-0215
|
pubmed:author |
pubmed-author:BreinigMarcoM,
pubmed-author:DienemannHendrikH,
pubmed-author:EhemannVolkerV,
pubmed-author:GunawanBastianB,
pubmed-author:KernMichael AMA,
pubmed-author:LichterPeterP,
pubmed-author:RadlwimmerBernhardB,
pubmed-author:RiekerRalf JRJ,
pubmed-author:SchirmacherPeterP,
pubmed-author:SchlaegerChristophC,
pubmed-author:SchnabelPhilipp APA,
pubmed-author:SchultenHans-JörgHJ,
pubmed-author:StegerChristina MCM
|
pubmed:copyrightInfo |
(c) 2008 Wiley-Liss, Inc.
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
122
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2719-25
|
pubmed:meshHeading |
pubmed-meshheading:18360827-Cell Line, Tumor,
pubmed-meshheading:18360827-Cell Separation,
pubmed-meshheading:18360827-Drug Screening Assays, Antitumor,
pubmed-meshheading:18360827-Female,
pubmed-meshheading:18360827-Flow Cytometry,
pubmed-meshheading:18360827-Humans,
pubmed-meshheading:18360827-Karyotyping,
pubmed-meshheading:18360827-Male,
pubmed-meshheading:18360827-Middle Aged,
pubmed-meshheading:18360827-Nucleic Acid Hybridization,
pubmed-meshheading:18360827-Thymoma,
pubmed-meshheading:18360827-Thymus Neoplasms
|
pubmed:year |
2008
|
pubmed:articleTitle |
Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma.
|
pubmed:affiliation |
Institute of Pathology, University Hospital, Heidelberg, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|